BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yeung MW, Wong GL, Choi KC, Luk AO, Kwok R, Shu SS, Chan AW, Lau ESH, Ma RCW, Chan HL, Chan JC, Wong VW, Kong AP. Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. J Hepatol. 2017;. [PMID: 28989092 DOI: 10.1016/j.jhep.2017.09.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Kawata N, Takahashi H, Iwane S, Inoue K, Kojima M, Kohno M, Tanaka K, Mori H, Isoda H, Oeda S, Matsuda Y, Egashira Y, Nojiri J, Irie H, Eguchi Y, Anzai K. FIB-4 index-based surveillance for advanced liver fibrosis in diabetes patients. Diabetol Int 2021;12:118-25. [PMID: 33479587 DOI: 10.1007/s13340-020-00453-7] [Reference Citation Analysis]
2 Han E, Kim MK, Jang BK, Kim HS. Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Diabetes Metab J 2021;45:698-707. [PMID: 33517613 DOI: 10.4093/dmj.2020.0118] [Reference Citation Analysis]
3 Mansour A, Mohajeri-Tehrani MR, Samadi M, Gerami H, Qorbani M, Bellissimo N, Poustchi H, Hekmatdoost A. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients. Acta Diabetol 2019;56:1199-207. [PMID: 31197470 DOI: 10.1007/s00592-019-01374-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
4 Kim MK. Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707). Diabetes Metab J 2021;45:968-9. [PMID: 34847645 DOI: 10.4093/dmj.2021.0311] [Reference Citation Analysis]
5 Truong E, Noureddin M. The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease. Clinics in Liver Disease 2022. [DOI: 10.1016/j.cld.2022.01.008] [Reference Citation Analysis]
6 Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 2020;69:1877-84. [PMID: 32381514 DOI: 10.1136/gutjnl-2019-319104] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 17.0] [Reference Citation Analysis]
7 Xin Z, Liu S, Niu J, Xu M, Wang T, Lu J, Chen Y, Wang W, Ning G, Bi Y, Xu Y, Li M, Zhao Z. The association of low-grade albuminuria with incident non-alcoholic fatty liver disease and non-invasive markers of liver fibrosis by glycaemia status. Liver Int 2021;41:101-9. [PMID: 32840963 DOI: 10.1111/liv.14649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Missikpode C, Kramer H, Cotler SJ, Durazo-Arvizu R, Lash JP, Kallwitz E, Cai J, Kuniholm MH, Rosas SE, Ricardo AC, Talavera GA, Raij L, Pirzada A, Daviglus ML. Association of elevated serum aminotransferase levels with chronic kidney disease measures: hispanic community health study/study of latinos. BMC Nephrol 2021;22:302. [PMID: 34493216 DOI: 10.1186/s12882-021-02483-y] [Reference Citation Analysis]
9 Ciardullo S, Ballabeni C, Trevisan R, Perseghin G. Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis. Biomolecules 2022;12:105. [DOI: 10.3390/biom12010105] [Reference Citation Analysis]
10 Saito H, Tanabe H, Kudo A, Machii N, Higa M, Yamaguchi S, Maimaituxun G, Abe K, Takahashi A, Tanaka K, Asahi K, Masuzaki H, Ohira H, Kazama JJ, Shimabukuro M. High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes. Sci Rep 2021;11:11753. [PMID: 34083571 DOI: 10.1038/s41598-021-88285-6] [Reference Citation Analysis]
11 Paik J, Golabi P, Younoszai Z, Mishra A, Trimble G, Younossi ZM, Negro F. Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. Liver Int 2019;39:342-52. [DOI: 10.1111/liv.13992] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
12 Hashimoto Y, Hamaguchi M, Kaji A, Sakai R, Kitagawa N, Fukui M. Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes. BMJ Open Diabetes Res Care 2020;8:e001189. [PMID: 32847841 DOI: 10.1136/bmjdrc-2020-001189] [Reference Citation Analysis]
13 Mantovani A, Zusi C, Dalbeni A, Grani G, Buzzetti E. Risk of Kidney Dysfunction IN Nafld. CPD 2020;26:1045-61. [DOI: 10.2174/1381612825666191026113119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Mantovani A, Turino T, Lando MG, Gjini K, Byrne CD, Zusi C, Ravaioli F, Colecchia A, Maffeis C, Salvagno G, Lippi G, Bonora E, Targher G. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab. 2019;. [PMID: 31786361 DOI: 10.1016/j.diabet.2019.11.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
15 Zhang X, Wong VW, Yip TC, Tse YK, Liang LY, Hui VW, Li GL, Chan HL, Wong GL. Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study. Hepatol Commun 2021;5:1212-23. [PMID: 34278170 DOI: 10.1002/hep4.1705] [Reference Citation Analysis]
16 Han E, Kim HS. Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707). Diabetes Metab J 2021;45:972-3. [PMID: 34847647 DOI: 10.4093/dmj.2021.0315] [Reference Citation Analysis]
17 Lee HW, Lee JS, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. J Diabetes Complications 2021;35:107747. [PMID: 33616043 DOI: 10.1016/j.jdiacomp.2020.107747] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Li X, Xia M, Ma H, Hu Y, Yan H, He W, Lin H, Zhao NQ, Gao J, Gao X. Liver fat content is independently associated with microalbuminuria in a normotensive, euglycaemic Chinese population: a community-based, cross-sectional study. BMJ Open 2021;11:e044237. [PMID: 34187816 DOI: 10.1136/bmjopen-2020-044237] [Reference Citation Analysis]
19 Baratta F, Pastori D, Angelico F, Balla A, Paganini AM, Cocomello N, Ferro D, Violi F, Sanyal AJ, Del Ben M. Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin Gastroenterol Hepatol. 2019; Epub ahead of print. [PMID: 31887443 DOI: 10.1016/j.cgh.2019.12.026] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
20 Lin H, Zhang X, Li G, Wong GL, Wong VW. Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. J Clin Transl Hepatol 2021;9:972-82. [PMID: 34966660 DOI: 10.14218/JCTH.2021.00201] [Reference Citation Analysis]
21 Maevskaya M, Kotovskaya Y, Ivashkin V, Tkacheva O, Troshina E, Shestakova M, Breder V, Geyvandova N, Doschitsin V, Dudinskaya E, Ershova E, Kodzoeva K, Komshilova K, Korochanskaya N, Mayorov A, Mishina E, Nadinskaya M, Nikitin I, Pogosova N, Tarzimanova A, Shamkhalova M. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii arkhiv. [DOI: 10.26442/00403660.2022.02.201363] [Reference Citation Analysis]
22 Kanbay M, Bulbul MC, Copur S, Afsar B, Sag AA, Siriopol D, Kuwabara M, Badarau S, Covic A, Ortiz A. Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease. J Nephrol 2021;34:649-59. [PMID: 32440840 DOI: 10.1007/s40620-020-00751-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Yang Q, Li X. The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population. Ann Hepatol 2021;25:100346. [PMID: 33864950 DOI: 10.1016/j.aohep.2021.100346] [Reference Citation Analysis]
24 Cernea S, Raz I. NAFLD in type 2 diabetes mellitus: Still many challenging questions. Diabetes Metab Res Rev 2021;37. [DOI: 10.1002/dmrr.3386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kiapidou S, Liava C, Kalogirou M, Akriviadis E, Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know? Ann Hepatol 2020;19:134-44. [PMID: 31606352 DOI: 10.1016/j.aohep.2019.07.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
26 Heda R, Yazawa M, Shi M, Bhaskaran M, Aloor FZ, Thuluvath PJ, Satapathy SK. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol 2021; 27(17): 1864-1882 [PMID: 34007127 DOI: 10.3748/wjg.v27.i17.1864] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Sun DQ, Ye FZ, Kani HT, Yang JR, Zheng KI, Zhang HY, Targher G, Byrne CD, Chen YP, Yuan WJ, Yilmaz Y, Zheng MH. Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD. Diabetes Metab 2020;46:288-95. [PMID: 31786360 DOI: 10.1016/j.diabet.2019.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
28 Perdomo CM, Garcia-Fernandez N, Escalada J. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate? J Clin Med 2021;10:2040. [PMID: 34068699 DOI: 10.3390/jcm10092040] [Reference Citation Analysis]
29 Chen PC, Kao WY, Cheng YL, Wang YJ, Hou MC, Wu JC, Su CW. The correlation between fatty liver disease and chronic kidney disease. J Formos Med Assoc. 2020;119:42-50. [PMID: 30876789 DOI: 10.1016/j.jfma.2019.02.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
30 von Loeffelholz C, Coldewey SM, Birkenfeld AL. A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. Cells 2021;10:1822. [PMID: 34359991 DOI: 10.3390/cells10071822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Ampuero J, Aller R, Gallego-durán R, Crespo J, Calleja JL, García-monzón C, Gómez-camarero J, Caballería J, Lo Iacono O, Ibañez L, García-samaniego J, Albillos A, Francés R, Fernández-rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Guerra MH, Augustín S, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero Gómez M. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. Journal of Hepatology 2020;73:17-25. [DOI: 10.1016/j.jhep.2020.02.028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
32 Ciardullo S, Ballabeni C, Trevisan R, Perseghin G. Reply to "Liver fibrosis assessed by transient elastography and albuminuria". Dig Liver Dis 2021;53:1056. [PMID: 33994126 DOI: 10.1016/j.dld.2021.04.003] [Reference Citation Analysis]
33 Loeffelholz CV, Roth J, Coldewey SM, Birkenfeld AL. The Role of Physical Activity in Nonalcoholic and Metabolic Dysfunction Associated Fatty Liver Disease. Biomedicines 2021;9:1853. [PMID: 34944668 DOI: 10.3390/biomedicines9121853] [Reference Citation Analysis]
34 Ciardullo S, Ballabeni C, Trevisan R, Perseghin G. Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population. Dig Liver Dis 2021;53:866-72. [PMID: 33685807 DOI: 10.1016/j.dld.2021.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Sumida Y, Yoneda M, Toyoda H, Yasuda S, Tada T, Hayashi H, Nishigaki Y, Suzuki Y, Naiki T, Morishita A, Tobita H, Sato S, Kawabe N, Fukunishi S, Ikegami T, Kessoku T, Ogawa Y, Honda Y, Nakahara T, Munekage K, Ochi T, Sawada K, Takahashi A, Arai T, Kogiso T, Kimoto S, Tomita K, Notsumata K, Nonaka M, Kawata K, Takami T, Kumada T, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone? Int J Mol Sci 2020;21:E4939. [PMID: 32668632 DOI: 10.3390/ijms21144939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]